Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 29, 2021 - Issue 1
Submit an article Journal homepage
323
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Sustained Remission with Tocilizumab in Refractory Relapsing Polychondritis with Ocular Involvement: A Case Series

Rebecca Farhata Ophthalmology Department, Rothschild Foundation Hospital, Paris, France;b Ophthalmology Department, Cochin Hospital, Paris, FranceORCID Iconhttps://orcid.org/0000-0001-9380-9201
, M.DORCID Icon,
Gaël Clavelc Internal Medicine Department, Rothschild Foundation Hospital, Paris, France
, M.D,
Delphine Villeneuvec Internal Medicine Department, Rothschild Foundation Hospital, Paris, France
, M.D,
Youssef Abdelmassiha Ophthalmology Department, Rothschild Foundation Hospital, Paris, FranceORCID Iconhttps://orcid.org/0000-0001-9887-0992
, M.DORCID Icon,
Marwan Sahyouna Ophthalmology Department, Rothschild Foundation Hospital, Paris, FranceORCID Iconhttps://orcid.org/0000-0002-5012-9473
, M.DORCID Icon,
Eric Gabisona Ophthalmology Department, Rothschild Foundation Hospital, Paris, FranceORCID Iconhttps://orcid.org/0000-0001-9457-3245
, M.DORCID Icon,
Thomas Senéc Internal Medicine Department, Rothschild Foundation Hospital, Paris, FranceORCID Iconhttps://orcid.org/0000-0002-3162-2537
, M.DORCID Icon,
Isabelle Cochereaua Ophthalmology Department, Rothschild Foundation Hospital, Paris, France
, M.D &
Cherif Titaha Ophthalmology Department, Rothschild Foundation Hospital, Paris, FranceCorrespondence[email protected]
, M.D show all
Pages 9-13 | Received 01 Mar 2020, Accepted 28 Apr 2020, Published online: 09 Jul 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

ABSTRACT

Objective: Describe our experience with tocilizumab in the treatment of refractory relapsing polychondritis with ocular involvement.

Methods: Retrospective consecutive interventional case series that included all patients that received tocilizumab for the treatment of relapsing polychondritis with ocular manifestations.

Results: Three cases were selected and the duration of tocilizumab treatment ranged from 1 to 2 years. One of our patients received tocilizumab as a first-line immunosuppressive treatment directly after prednisone. All achieved complete response to tocilizumab 1 month after treatment initiation. No advert events were reported during the follow-up period except for transient neutropenia without any associated infection.

Conclusion: Our three cases suggest that tocilizumab may be an effective and safe treatment for ocular manifestation associated with relapsing polychondritis.

Disclosure statement

None of the authors has conflict of interest with the submission.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 815.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.